Hotspot mutations in the FGFR3 gene (R248C, S249F/C, G372C, and Y375C (missense gain-of-function mutations)) and upstream of the TERT promoter (C228T and C250T (gain-of-function mutations)) are often identified in urothelial carcinoma samples [11,12,13]. This evidence concerns the gene FGFR3 and urothelial carcinoma.